AR and COVID-19: Using the NBT assay, we measured the in vitro ROS activity by analyzing the activation of neutrophils from patients with COVID-19 in the presence of increasing concentrations of the androgen receptor agonist DHT (at the physiological concentration of 1 nM (290 pg/mL) or at a supraphysiological concentration ≥10 nM (2904 pg/mL)) or the antagonist flutamide (100 nM).